Pancreatic cancer is a serious condition that can be difficult to recognise in its early stages. Symptoms such as abdominal discomfort, loss of appetite or unexplained weight loss may resemble more common digestive problems, making it challenging to identify the disease from symptoms alone.
Although pancreatic cancer can be difficult to treat, advances in diagnosis and treatment are helping doctors develop more individualised care plans for selected patients.
Understanding the symptoms, risk factors and available treatment options can help patients and families make informed decisions about their healthcare.
What Is Pancreatic Cancer?
The pancreas is an organ located behind the stomach. It produces digestive enzymes that help break down food and hormones, including insulin, that help regulate blood sugar levels.
Pancreatic cancer develops when abnormal cells in the pancreas grow uncontrollably and form a malignant tumour.
The most common type is pancreatic ductal adenocarcinoma (PDAC), which develops from cells associated with the pancreatic ducts.
Other, less common tumours, such as pancreatic neuroendocrine tumours, behave differently and may require different treatments. The information below primarily concerns pancreatic ductal adenocarcinoma.
Pancreatic Cancer in India: Why Awareness Matters
Pancreatic cancer represents a smaller proportion of cancer diagnoses in India than several more common cancers. However, it remains an important concern because symptoms are often difficult to recognise early.
According to GLOBOCAN 2022 estimates, approximately 511,000 new cases of pancreatic cancer occurred worldwide in 2022.
The Indian Consensus Guidelines for the Management of Pancreatic Cancer, published in 2025, emphasise the importance of appropriate diagnostic evaluation, multidisciplinary treatment planning and supportive care.
Greater awareness can help individuals recognise concerning symptoms and seek appropriate medical attention without unnecessary delay.
What Are the Symptoms of Pancreatic Cancer?
Pancreatic cancer may not cause noticeable symptoms in its early stages. When symptoms develop, they may include:
- Persistent pain or discomfort in the upper abdomen, sometimes extending to the back.
- Unexplained weight loss or reduced appetite.
- Yellowing of the skin or eyes, known as jaundice.
- Dark urine, pale stools or itching.
- Nausea or changes in digestion.
- Newly diagnosed diabetes or an unexpected worsening of blood sugar control in some individuals.
These symptoms do not necessarily indicate pancreatic cancer. Many can occur with common digestive, liver or metabolic conditions.
However, persistent or unexplained symptoms should be evaluated by a healthcare professional. New jaundice, particularly when accompanied by dark urine or pale stools, requires prompt medical assessment.
What Are the Risk Factors for Pancreatic Cancer?
Pancreatic cancer does not have a single known cause. Several factors may increase the likelihood of developing the disease.
Having these risk factors does not mean someone will develop the disease. Individuals with a strong family history may benefit from specialist genetic risk assessment.
-
Smoking:
Tobacco use is an important, modifiable risk factor.
-
Increasing age:
The risk generally increases with age, particularly in older adults.
-
Family history:
Having close relatives with pancreatic cancer may increase risk, especially when multiple family members have been affected.
-
Inherited genetic factors:
Certain inherited genetic changes, including those involving BRCA1, BRCA2 and other cancer-predisposition genes, may increase susceptibility.
-
Chronic pancreatitis:
Long-standing inflammation of the pancreas is associated with increased risk.
-
Diabetes and obesity:
Both have been associated with pancreatic cancer, although these relationships are complex. Diabetes is common and does not, by itself, suggest pancreatic cancer.
How Is Pancreatic Cancer Diagnosed?
Because early symptoms can be non-specific, doctors may recommend several investigations based on the patient’s clinical condition.
-
Clinical examination and blood tests
The doctor reviews symptoms, medical history and examination findings. Blood tests may help assess liver function, bilirubin levels and other health parameters.
CA 19-9 is a tumour-associated blood marker that may be used alongside other investigations to assess or monitor pancreatic cancer. However, it can also be elevated in non-cancerous conditions and cannot reliably diagnose pancreatic cancer on its own.
-
Imaging tests
A contrast-enhanced CT scan using a pancreatic protocol is commonly used to assess a suspected tumour and its relationship with surrounding structures. MRI or other imaging may be recommended when appropriate.
-
Endoscopic ultrasound and biopsy
Endoscopic ultrasound can provide detailed images of the pancreas and help obtain tissue samples when required.
A biopsy may be needed to confirm the diagnosis, particularly before non-surgical cancer treatment. In selected patients undergoing surgery for a strongly suspected resectable tumour, a preoperative biopsy may not always be necessary.
-
Assessment of disease extent
Doctors assess whether the cancer is confined to the pancreas, involves nearby blood vessels or has spread to other organs. This information helps guide treatment planning.
Understanding Pancreatic Cancer Stages and Treatment Planning
Pancreatic cancer has formal cancer stages, but doctors also classify the disease according to whether surgery is possible.
The main treatment-planning categories include:
- Resectable: The cancer may be removed surgically.
- Borderline resectable: Surgery may be possible, often after additional treatment.
- Locally advanced: The cancer involves nearby structures and generally cannot be removed immediately.
- Metastatic: The cancer has spread to distant organs, such as the liver or lungs.
These categories help specialists decide which treatments may be appropriate.
What Are the Treatment Options for Pancreatic Cancer?
Treatment depends on the cancer’s extent, tumour characteristics, the patient’s overall health and individual treatment goals.
-
Surgery
Surgery offers the possibility of long-term disease control or cure in selected patients whose cancer can be completely removed. Procedures may include the Whipple operation or removal of part of the pancreas, depending on the tumour's location.
-
Chemotherapy
Chemotherapy is an important treatment for many patients. It may be given before or after surgery or used to help control locally advanced or metastatic disease.
-
Radiotherapy
Radiotherapy may be considered for selected patients, particularly in certain locally advanced or borderline resectable situations. It is not routinely required for everyone with pancreatic cancer.
-
Targeted therapy
Some patients may be eligible for treatments based on specific inherited genetic changes or tumour biomarkers.
For example, selected patients with metastatic pancreatic adenocarcinoma and inherited BRCA1 or BRCA2 mutations, whose cancer has not progressed after at least 16 weeks of first-line platinum-based chemotherapy, may be considered for maintenance treatment with a PARP inhibitor, subject to clinical suitability and applicable approvals.
-
Immunotherapy
Immunotherapy is not routinely used for most pancreatic cancers. However, selected patients with specific biomarkers, such as mismatch-repair deficiency or high microsatellite instability, may be considered for immune checkpoint inhibitors under appropriate clinical indications.
Treatment decisions should be made by a specialist multidisciplinary team after discussing expected benefits, limitations and possible side effects.
Emerging Therapies: What Does the Future Hold?
Research is exploring new approaches to pancreatic cancer treatment, including therapies directed at specific genetic alterations, new drug combinations and methods of identifying the disease earlier.
Molecular testing may help identify certain patients who could benefit from specific treatments or relevant clinical trials.
However, many emerging approaches remain experimental. Their safety, effectiveness, approval status and suitability must be established for the particular clinical situation.
Patients interested in new treatments should discuss available evidence and clinical-trial options with their oncology team.
Supportive Care During Pancreatic Cancer Treatment
Supportive care is an important part of managing pancreatic cancer.
Depending on individual needs, it may include nutritional counselling, pancreatic enzyme replacement, diabetes management, pain relief and psychological support.
Palliative care can also help manage symptoms and improve quality of life. It is not limited to end-of-life care and may be provided alongside active cancer treatment.
Regular communication with the healthcare team can help patients and families manage symptoms, treatment-related challenges and changing care needs.
Frequently Asked Questions About Pancreatic Cancer
Why is pancreatic cancer often diagnosed late?
Early-stage pancreatic cancer may cause few or non-specific symptoms. Diagnosis often requires targeted medical evaluation and imaging.
Can a blood test detect pancreatic cancer?
No routine blood test can reliably screen the general population for pancreatic cancer. CA 19-9 may support clinical assessment but cannot independently confirm or rule out the disease.
Is surgery possible for pancreatic cancer?
Surgery may be possible in selected patients, depending on the cancer's location, extent and the patient's overall health. A specialist team determines whether surgery is appropriate.
Is routine pancreatic cancer screening recommended?
Routine screening is not recommended for the general population. People with certain inherited genetic risks or a strong family history may benefit from specialist assessment and, in selected cases, surveillance.
Conclusion: Awareness and Informed Care Matter
Pancreatic cancer remains a challenging disease, but appropriate diagnosis, individualised treatment planning and supportive care are important components of its management.
Recognising persistent symptoms, understanding personal risk factors and seeking medical advice when needed can support informed healthcare decisions.
At WeEmbrace Biopharma, we believe accessible, evidence-informed cancer education helps patients and caregivers better understand their healthcare journey.
References and Further Reading
- International Agency for Research on Cancer (IARC). Global Cancer Observatory: GLOBOCAN 2022 – Pancreas Fact Sheet.
https://gco.iarc.who.int/media/globocan/factsheets/cancers/13-pancreas-fact-sheet.pdf - Lavingia V, et al. Indian Consensus Guidelines for the Management of Pancreatic Cancer. Indian Journal of Medical and Paediatric Oncology. 2025;46(5):435–452.
https://doi.org/10.1055/s-0045-1811946 - National Cancer Institute. Pancreatic Cancer Treatment (PDQ®) – Health Professional Version.
https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq - National Cancer Institute. Pancreatic Cancer Screening (PDQ®) – Health Professional Version.
https://www.cancer.gov/types/pancreatic/hp/pancreatic-screening-pdq
Medical Disclaimer
This article is intended for general educational and informational purposes only. It does not replace professional medical advice, diagnosis or treatment. Decisions regarding pancreatic cancer screening, diagnostic investigations and treatment should be individualised in consultation with a qualified healthcare professional. Readers experiencing persistent or concerning symptoms should seek appropriate medical evaluation.
